COMBINED VALUE OF IODINE-123 META-IODOBENZYLGUANIDINE MYOCARDIAL IMAGING AND THE SEATTLE HEART FAILURE MODEL IN PREDICTION OF MORTALITY AMONG HEART FAILURE PATIENTS  by Ketchum, Eric S. et al.
E654
JACC April 5, 2011
Volume 57, Issue 14
  IMAGING AND DIAGNOSTIC TESTING 
COMBINED VALUE OF IODINE-123 META-IODOBENZYLGUANIDINE MYOCARDIAL IMAGING AND THE 
SEATTLE HEART FAILURE MODEL IN PREDICTION OF MORTALITY AMONG HEART FAILURE PATIENTS
ACC Oral Contributions
Ernest N. Morial Convention Center, Room 254
Tuesday, April 05, 2011, 3:00 p.m.-3:15 p.m.
Session Title: Nuclear Cardiology/PET: Applications, Accuracy and Prognosis
Abstract Category: 39. Nuclear Cardiology/PET
Presentation Number: 926-7
Authors: Eric S. Ketchum, Arnold F. Jacobson, James H. Caldwell, Roxy Senior, Manuel D. Cerqueira, Gregory S. Thomas, Denis Agostini, Jagat Narula, 
Wayne Levy, University of Washington, Seattle, WA
Background:  ADMIRE-HF reported the predictive value of iodine-123 meta-iodobenzylguanidine (MIBG) imaging for identifying heart failure (HF) 
patients at increased risk of adverse events. The Seattle Heart Failure Model (SHFM) is a multivariate model that predicts survival in patients with 
HF. We examined the combined prognostic value of MIBG and the SHFM in the ADMIRE-HF cohort.
Methods:  961 subjects with New York Heart Association (NYHA) functional class II/III HF and left ventricular ejection fraction (LVEF) ≤ 35% 
were studied. Survival data from the original study and additional follow-up collected on 470 subjects are included in this analysis (1678 total 
person-years of follow-up). All cause mortality predictions from the SHFM were compared with predictions obtained with addition of late heart to 
mediastinum ratio (H/M) results from MIBG imaging.
Results:  100 deaths occurred during a median follow-up of 2 years. The SHFM predicted survival at 1 year was 94.4%, virtually identical to 
the observed rate of 94.6%. A multivariate Cox Proportional Hazard analysis showed improvement in SHFM discriminant ability for all-cause 
mortality with the addition of H/M (p=0.0002). For a 1 standard deviation (SD) increase in the SHFM score the risk doubled (hazard ratio (HR) 
1.98, p<0.001), whereas for a 1 SD decrease in H/M the risk increased 56% (HR 1.56, p=0.002). For subjects in the highest risk SHFM quintile 
(estimated 2 year survival of 76%), those with the most favorable (≥ 1.6) H/M (n=30) showed significantly greater 2 year survival (83.6%) than 
subjects with the most unfavorable (≤ 1.2) H/M (n=31) (57%, p=.03). The net reclassification improvement and integrated discrimination index for 
the combined model were both significant (p < 0.0001).
Conclusion: The addition of H/M to the SHFM adds to predictive ability for all-cause mortality. This is greatest in patients in the highest-risk SHFM 
group. By improving risk prediction, use of MIBG imaging may aid in patient selection for invasive devices (e.g.: CRT, LVAD) in advanced heart failure.
